biostudies-literatureKo SHAcademia Sinica Key and Novel Therapeutics Development Program for Major DiseasesEmerging Infectious and Major Disease Research Program108https://www.ebi.ac.uk/biostudies/studies/S-EPMC9774083biostudies-literatureUnknown29(1)<h4>Background</h4>The variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) harbor diverse spike (S) protein sequences, which can greatly influence the efficacies of therapeutics. Therefore, it would be of great value to develop neutralizing monoclonal antibodies (mAbs) that can broadly recognize multiple variants.<h4>Methods</h4>Using an mRNA-LNP immunization strategy, we generated several mAbs that specifically target the conserved S2 subunit of SARS-CoV-2 (B-S2-mAbs). These mAbs were assessed for their neutralizing activity with pseudotyped viruses and binding ability for SARS-CoV-2 variants.<h4>Results</h4>Among these mAbs, five exhibited strong neutralizing ability toward the Gamma variant and also recognized viral S proteins from the Wuhan, Alpha, Beta, Gamma, DelJournal of biomedical scienceMonoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.PMC9774083AS-KPQ-111-KNTAS-KPQ-111-EIMDLin HTHsu FFKo SHWu HCKe FYFu CYSu SCLiang KHChen WYKumari MfalseMonoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.<h4>Background</h4>The variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) harbor diverse spike (S) protein sequences, which can greatly influence the efficacies of therapeutics. Therefore, it would be of great value to develop neutralizing monoclonal antibodies (mAbs) that can broadly recognize multiple variants.<h4>Methods</h4>Using an mRNA-LNP immunization strategy, we generated several mAbs that specifically target the conserved S2 subunit of SARS-CoV-2 (B-S2-mAbs). These mAbs were assessed for their neutralizing activity with pseudotyped viruses and binding ability for SARS-CoV-2 variants.<h4>Results</h4>Among these mAbs, five exhibited strong neutralizing ability toward the Gamma variant and also recognized viral S proteins from the Wuhan, Alpha, Beta, Gamma, Del2022-01-01T00:00:00Z2022 Dec2025-04-19T20:35:35.962Z2025-04-19T20:35:35.962ZS-EPMC97740833655057010.1186/s12929-022-00891-2